Fount of Information

TriLink BioTechnologies社 January TriLink Messenger





Research News


Jan_Messenger_3.pngSelf-Amplifying RNA Vaccines—What to Know

Unlike conventional mRNA vaccines, which only encode the antigen of interest and are translated directly from the incoming mRNA molecules, saRNA can generate many copies of RNA in the target cell.
For this month's Zon blog, we selected several publications on saRNA to highlight self-amplifying RNA vaccines.

Read More

Jan_Messenger_4.pngContinued innovation promises new and improved mRNA-based therapeutics

Jan_Messenger_5.pngCRISPR-engineered universal T cells provide a novel approach to treating cancer

TriLink’s CleanCap® technology featured in a recent Nature Medicine review of mRNA nanomedicine, which highlights the importance of co-transcriptional capping to reduce unwanted immunostimulation and increase translation efficiencies. Researchers at Great Ormond Street Hospital for Children and Great Ormond Street Institute of Child Health used TriLink-manufactured mRNA in a next-generation CAR T-cell therapy, providing complete remission from B-cell acute lymphoblastic leukemia in a phase 1 clinical trial.
Read More Read More

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。